CRP and Venous thrombosis: The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) trial showed that the monoclonal antibody canakinumab directed against IL-1B was effective in reducing recurrent cardiovascular events in patients with prior MI and elevated CRP (4).